Community-acquired pneumonia (CAP) is the leading cause of death from infectious disease in western countries and supposes an important consumption of healthcare resources. Several studies suggest that proADM is possibly as good as validated severity scores in detecting critically ill patients with CAP and probably better than other biomarkers like procalcitonin (PCT).
No takes yet. Share an insight, caveat, or question.
Suberviola et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: